De novo mutations in autism spectrum disorders and an empirical test of the neutral DNA model

Ye Zhang and Shi Huang*

Center for Medical Genetics, School of Life Sciences, Xiangya Medical School, Central South University, Changsha, Hunan 410078, People's Republic of China

*Corresponding author.
Email: huangshi@sklmg.edu.cn

Keywords: autism, de novo mutations, parity rule, AT content, neutral theory, infinite site, maximum genetic diversity hypothesis

Short title: De novo mutations in autism and an empirical test of neutrality

Abstract

The genetic basis of autism spectrum disorders (ASD) remains better understood and might concern only a small fraction of the genome if the neutral theory were true. We here analyzed published de novo single nucleotide variations in ASD and controls to better understand de novo mutations (DNMs) and to empirically test the neutral model. By comparing DNMs in ASD and control subjects with single nucleotide polymorphisms (SNPs) found in the 1000 genomes project, we found that DNMs in normal subjects occurred at SNP sites at least 3.45 fold more frequent than expected from the neutral theory, whereas DNMs in ASD were less frequent (2.81 fold), especially so for common SNPs with minor allele frequency >0.01 (0.97 fold in ASD vs 1.81 fold in normal). We also analyzed the nucleotide compositions of DNMs and the parity (1:1 ratio) of pyrimidines and purines (Chargaff Parity Rule 1 and 2). We found that DNMs in ASD showed overall lower AT content than that in controls ($P<0.05$). Parity violations and AT bias in DNMs occurred at expected frequency based on chance (~0.05) in both ASD and controls. However, no individual was found to have both parity violation and AT bias among 290 normal and 429 ASD subjects studied. These results show enrichment of DNMs in SNP sites in normal subjects and less so in ASD, which is not expected from the neutral model, and indicate that DNMs are on average more deleterious in ASD than in controls.

Introduction:

Autism spectrum disorders (ASD) is a common disease today with a prevalence of 14.6 per 1,000 (one in 68) children aged 8 years in the United States at 2012 [1]. It is four times more common in males than in females [2, 3]. Twin and family studies show that siblings of children with ASD are at a significant higher risk for autism than the general population [4-6]. ASD remains poorly understood but may have a strong genetic component with a heritability of 40–80% [7-10]. ASD are genetically highly heterogeneous, with no single gene accounting for more than 1% of cases [11].

Recent work has shown a substantial contribution of de novo variations [12-15]. Probands of ASD, relative to unaffected siblings, have been found to more likely carry multiple coding and noncoding DNMs in different genes, which are enriched for expression in striatal neurons [16]. Genome-wide association studies have revealed few replicable common polymorphisms associated with ASD [17-20]. Common genetic variants are individually of little effect but acting additively may be a major source of risk for autism [21]. Assortative mating may play a role in bringing about enrichment of ASD alleles in an affected child [22]. Consistent with the notion of collective and additive effects of common variants, recent studies indicate a role for genome wide minor allele content (MAC) of an individual in a variety of complex traits and diseases [23-26]. The more the number of minor alleles of common SNPs in an individual, the higher the risk in general for many complex diseases such as type 2 diabetes, schizophrenia, and Parkinson's disease [23-28]. Such findings indicate an optimum level of genetic variations that an individual can tolerate [29, 30].

Nucleotide positions of common SNPs found in normal populations such as in the

1000 genomes cohort are presumably less conserved than those regions of genome that are deficient in SNPs. The neutral theory considers it a null hypothesis that most of the human genome (~90%) to be freely changeable or selectively neutral [31]. However, it remains to be empirically verified whether the SNP depleted regions of the genome can freely tolerate DNMs as expected from the neutral theory. While DNMs in ASD have been found to be enriched in deleterious mutations relative to those in normal subjects [16], it remains unknown whether most DNMs in ASD occur more often in the genomic regions deficient in SNPs.

In this study, we investigated whether DNMs in ASD are more enriched in the SNP deficient sites relative to those in normal subjects and whether DNMs in normal subjects may show preference for the common SNP sites. We also studied nucleotide composition patterns in DNMs in ASDs in terms of AT content (human genome is known to be ~58% AT) and Chargaff's Parity Rule 1 and 2 (the 1:1 ratio of pyrimidines and purines) [32, 33]. We found that DNMs in ASDs were enriched in positions deficient in common SNPs and that DNMs in normal individuals occurred more often in the common SNP sites. DNMs in ASD showed lower AT content but normal parity patterns. The results do not support the neutral model.

Results:

DNMs were enriched in sites of common SNPs and less so in ASD

We made use of the DNM database NPdenov [34] to study the genomic mutation patterns in ASD. We focused on SNVs and studied 50281 DNMs in control subjects and

28376 DNMs in ASD that were discovered by whole genome sequencing. We matched the positions of these DNMs with the SNP sites detected in the 1000 genomes project (1KGP) phase 3 dataset [35]. The fraction of DNM sites matching the SNP sites of 1KGP (total SNPs numbers 81,377,202) in ASD was found lower than that in the control subjects (2056/28376 or 0.073 vs 4457/50280 or 0.089, P < 0.001, chi square test, Table 1). For SNPs with minor allele frequency (MAF) >0.01 in the 1KGP (numbers 12,200,686), the matches were only 108/28376 or 0.0038 for DNM in ASD versus 354/50280 or 0.0070 for DNM in controls (P < 0.001, chi square test). Also in the case of ASD, the fraction of all SNPs matched with DNMs was 2.8 times that of higher MAF (>0.01) SNPs matched with DNMs (0.000025 vs 0.0000089, P<0.01), whereas in the case of controls, the fraction of all SNPs matched with DNMs was only 1.9 times that of higher MAF (>0.01) SNPs matched with DNMs (0.000055 vs 0.000029, P<0.01, Table 1), indicating again that DNMs in ASD cases occurred more often in the rare SNP sites. These results show a preferential depletion of DNMs in SNPs, especially for the common ones (MAF>0.01), in ASD relative to controls.

Table 1. Matches of DNM sites with SNP sites. The numbers of DNMs used were 28376 and 50280 for ASD and normal subjects, respectively. The numbers of SNPs compared were 81377202 and 12200686 for all SNPs and common SNPs with MAF>0.01, respectively.

	ASD cases		**Controls**	
Fractions matched	**DNM**	**SNPs**	**DNM**	**SNPs**
All SNPs	0.0725		0.089***	
All DNMs		0.000025		0.000055
SNPs (MAF>0.01)	0.0038		0.007***	
DNMs (MAF>0.01)		0.0000089**		0.000029**

***, P< 0.001, ASD cases vs controls, chi squared test;
** , P< 0.01, All SNPs vs SNPs with MAF>0.01.

We analyzed 81.4 million SNPs in 1KGP representing 2.58% of the total number of bases in the GRCh37 hg19 genome (3.156 billion). If most sites in the genome are neutral and can accommodate mutations equally, one would expect ~2.58% of DNMs to overlap with SNPs. In fact, the neutral theory predicts this percentage to be much lower since its infinite site model means that new mutations should mostly occur at never before mutated sites. However, the observed percentage in normal subjects, 8.9% (Table 1), was 3.45 fold higher than the expected value, which was likely an underestimation. This could be accounted for only if just 29% of the genome can freely accommodate mutations.

There were 12.2 million SNPs with MAF>0.01 in 1KGP representing 0.39% of the genome. The observed percentage of DNMs matching SNPs with MAF>0.01 in normal subjects was 0.7% in normal subjects and 0.38% in ASD cases. So, the percentage in normal subjects was 1.81 fold higher than expected while the percentage in ASD cases was similar to or slightly lower than the expected value. These observations show that DNMs in normal subjects did not, whereas DNMs in ASD cases did to some extent, conform to descriptions by the neutral theory. So, most parts of the genome (71%) may not freely tolerate mutations that can survive as DNMs in healthy individuals. If de novo mutations do occur mostly on new sites as predicted by the neutral theory and its infinite site model, they would produce a pattern similar to that in the ASD cases but unlike that in the normal subjects, and hence be associated with diseases.

DNMs in ASD were AT deficient but conformed to parity rules

The human genome shows unexplained AT-bias in base compositions (~58%). However, the overall AT content in DNMs in ASD cases showed less AT than controls (16017/28376 or 56.4% in ASD vs 28754/50281 or 57.2% AT in controls, P<0.05). To study AT content variation of DNMs among individuals, we examined 290 normal and 429 ASD individuals with 30-100 DNMs per individual. Among 429 ASD samples studied (Table 2), 7 (1.6%) showed AT bias (defined as higher than 58% AT, P<0.05) and 28 (6.5%) showed GC bias (defined as higher than 42% GC, P<0.05). In comparison, among 290 controls studied, two (0.69%) showed AT bias and 12 (4.1%) showed GC bias (P<0.05). The incidence of GC bias in ASD was higher than that in controls (P<0.05, chi squared test). The results showed that DNMs in ASD were significantly different from those in normal subject in being AT deficient.

Table 2. AT content analyses. AT bias was defined as having AT percentage at greater than 58% (P<0.05) in DNMs of an individual. GC bias was defined as having GC percentage at greater than 42%.

	AT %	**AT bias %**	**GC bias %**
ASD	56.4	1.6	6.5
Controls	57.2	0.69	4.1
P value	< 0.05	> 0.05	< 0.05

DNMs are thought to occur randomly and expected to follow the 1:1 ratio of pyrimidines and purines (Chargaff's Parity Rule 1 and 2). Random mutation process predicts that parity should hold for bases either targeted for (reference alleles) or resulting from mutations (alternative alleles). We confirmed this in our survey of 50281

DNMs in normal individuals as reported in the literature (25016 TC vs 25265 AG for reference alleles, and 25140 TC vs 25141 AG for alternative alleles). This pattern also held similarly in 28376 DNMs in ASD (14167 TC vs 14209 AG for reference alleles, and 14308 TC vs 14068 AG for alternative alleles). Therefore, one expects that mutations causing parity violations would qualify as non-random, in the same sense as a biased coin toss. We examined 290 normal and 429 ASD individuals with 30-100 DNMs per individual and found 4.8% (14/290) and 4.2 % (18/429) with parity violations ($P<0.05$), respectively. However, none of these were significant after adjustment for multiple testing. The rate of ~5% parity violations in the general population or ASD cases was consistent with the random chance of a nonrandom event as defined by $P < 0.05$. The results indicated that DNMs in ASD did not differ in conforming to parity rules from those in control subjects.

Of 18 ASD samples with parity violations, none showed AT bias and 4 showed GC bias (GC bias as defined by significantly greater than 42%, $P<0.05$). Of 14 normal samples with parity violations, none showed AT bias and one showed GC bias. Thus, of 32 samples with parity violations among 719 samples examined (290 normal and 429 ASD), none showed both parity violation and AT bias (incidence rate < 1/719 or 0.0014). Given the observed random rate of violating the parity rule and the AT bias pattern being 0.0445 and 0.0125, respectively, one would expect the random rate of violating both parity and AT bias pattern to be 0.00056, too low to be observed with the sample size studied here (719).

Discussion:

To better understand the genetics of ASD and the issue of neutral DNAs, we studied the genomic patterns of DNMs in ASD and normal subjects. Our results showed that DNMs in ASD were more enriched in the conserved regions of the genome that are deficient in common SNPs, which is consistent with previous findings of ASD probands carrying more DNMs with deleterious effects [16]. This suggests that the conserved regions of the genome are under natural selection.

The neutral model explains the extremely low genetic diversity of humans, in particular non-Africans, by postulating bottlenecks in the past, which would predict higher and higher genetic diversity in non-Africans with no limit defined. Most of the regions devoid of SNPs are assumed to be neutral or not under natural selection. Under such neutral assumption, one would not necessarily expect the locations of most DNMs in ASD to be different from those in control subjects. In particular, the infinite site assumption of the neutral model is a prerequisite for most studies in the population genetics field and predicts that most DNMs should occur at new sites (have not had mutations before) and hence not to be enriched in SNP sites [36]. In contrast, the maximum genetic diversity (MGD) hypothesis postulates that nearly all DNAs in humans are functional and that most mutations and SNPs are deleterious [37, 38]. Therefore, the MGD hypothesis predicts that DNMs should be more enriched in SNP sites and that recurrent mutations should be common.

Our results here indicate that 71% of the genome may not be free to incur de novo mutations, which is much greater than the fraction of the genome (~10%) that are

estimated to be functional [31]. The results therefore invalidate the neutral model and its infinite site assumption and support the MGD hypothesis. That SNP sites were preferentially hit by new DNMs was consistent with the finding of saturated or maximum genetic diversity as observed in present day human populations [39]. Sharing of common SNPs between different populations appear to be due to recurrent mutations rather than common ancestry. The neutral null hypothesis has been mostly tested previously by computational approaches based on uncertain assumptions that take certain sequences to be neutral for granted (repeats, viral sequences, and non-conserved regions) [31]. Recent empirical studies comparing genetic diversities of patient and control populations have all contradicted the neutral model [25, 27, 28, 30]. The results here provide additional empirical evidence not favoring the neutral hypothesis. The rapid advances in genomics in recent decades have made it practically possible for the first time to empirically test most of the uncertain assumptions in the field of population genetics and molecular evolution, and we expect more experimental tests to be performed in the near future. Reestablishing more realistic and certain assumptions will be key for the field to produce realistic conclusions that can actually find support from findings in other fields.

Because the collective effect of SNPs in numerous complex traits and diseases [25, 27, 28, 30], even common SNPs are also mostly not neutral and only more neutral relative to the more conserved regions of the genome. Such observations therefore would further substantially reduce the fraction of neutral sites in the human genome.

Base mutations appear to have a bias in the direction of A:T and newly emerged low-frequency SNP alleles are typically A:T rich [40, 41]. Interestingly, derived species appear

to show more AT bias than ancestral species, and the direction of evolution appears to be going towards higher AT content [33]. Our observation here of less AT content in DNMs of ASD indicates that AT content in DNMs of ASD was abnormal and against the trend of evolution. This may be related to the enigma of how AT content stays at a certain biased level not expected from random chance. Negative selection due to diseases such ASD may prevent AT content from increasing without limit.

Parity rules appear to apply in DNMs in both ASD and control subjects. Individuals with parity violations or AT bias exist in frequencies expected by random chance (~0.5%) in both ASD and controls. This confirms that DNMs occur mostly in a random fashion and obey probability rules. The event of both parity violation and AT bias in DNMs in an individual appears to be rare and future larger sample size studies are required to reveal whether such event may occur in reality.

Materials and Methods:

DNMs data from ASD and normal subjects were downloaded from NPdenovo database [34]. These DNMs were all found by whole genome sequencing analyses. For SNPs, we downloaded vcf files of the 1KGP phase 3 dataset [35]. We used MAF data in the vcf file based on all ~2500 individuals in the 1KGP.

Data manipulations were done using custom scripts. Standard statistics methods were used including chi squared test (2 tailed) and Bonferroni correction for multiple testing.

Acknowledgments:

We thank Jinchen Li for help with the NPdenovo database. This work was supported by the National Natural Science Foundation of China grant 81171880 and the National Basic Research Program of China grant 2011CB51001 (S.H.).

Author Contributions:

YZ and SH designed the analysis, analyzed data and wrote paper.

References:

1. Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN *et al.* Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. *MMWR Surveill Summ* 2016; **65**(3)**:** 1-23.

2. Lord C, Schopler E, Revicki D. Sex differences in autism. *J Autism Dev Disord* 1982; **12**(4)**:** 317-330.

3. Wing L, Wing JK. *Early childhood autism : clinical, educational, and social aspects*. 2d edn. Pergamon Press: Oxford ; New York, 1976, xii, 342 p.pp.

4. Wood CL, Warnell F, Johnson M, Hames A, Pearce MS, McConachie H *et al.* Evidence for ASD recurrence rates and reproductive stoppage from large UK ASD research family databases. *Autism Res* 2015; **8**(1)**:** 73-81.

5. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E *et al.* Autism as a strongly genetic disorder: evidence from a British twin study. *Psychol Med* 1995; **25**(1)**:** 63-77.

6. Geschwind DH. Advances in autism. *Annu Rev Med* 2009; **60:** 367-380.

7. Geschwind DH. Genetics of autism spectrum disorders. *Trends Cogn Sci* 2011; **15**(9)**:** 409-416.

8. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T *et al.* Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen*

Psychiatry 2011; **68**(11)**:** 1095-1102.

9. Robinson EB, Koenen KC, McCormick MC, Munir K, Hallett V, Happe F *et al.* A multivariate twin study of autistic traits in 12-year-olds: testing the fractionable autism triad hypothesis. *Behav Genet* 2012; **42**(2)**:** 245-255.

10. Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB *et al.* Most genetic risk for autism resides with common variation. *Nat Genet* 2014; **46**(8)**:** 881-885.

11. Chahrour MH, Yu TW, Lim ET, Ataman B, Coulter ME, Hill RS *et al.* Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. *PLoS Genet* 2012; **8**(4)**:** e1002635.

12. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; **515**(7526)**:** 216-221.

13. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ *et al.* De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* 2012; **485**(7397)**:** 237-241.

14. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP *et al.* Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* 2012; **485**(7397)**:** 246-250.

15. Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A *et al.* Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* 2012; **485**(7397)**:** 242-245.

16. Turner TN, Coe BP, Dickel DE, Hoekzema K, Nelson BJ, Zody MC *et al.* Genomic Patterns of De Novo Mutation in Simplex Autism. *Cell* 2017; **171**(3)**:** 710-722 e712.

17. Devlin B, Melhem N, Roeder K. Do common variants play a role in risk for autism? Evidence and theoretical musings. *Brain Res* 2011; **1380:** 78-84.

18. Pan Y, Chen J, Guo H, Ou J, Peng Y, Liu Q *et al.* Association of genetic variants of GRIN2B with autism. *Sci Rep* 2015; **5:** 8296.

19. Xia K, Guo H, Hu Z, Xun G, Zuo L, Peng Y *et al.* Common genetic variants on 1p13.2 associate with risk of autism. *Mol Psychiatry* 2014; **19**(11)**:** 1212-1219.

20. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS *et al.* Common genetic variants on 5p14.1 associate with autism spectrum disorders. *Nature* 2009; **459**(7246)**:** 528-533.

21. Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ *et al.* Common genetic variants, acting additively, are a major source of risk for autism. *Mol Autism* 2012; **3**(1)**:** 9.

22. Zhu Z, Lu X, Yuan D, Huang S. Close genetic relationships between a spousal pair with autism-affected children and high minor allele content in cases in autism-associated SNPs. *Genomics* 2017; **109**(1)**:** 9-15.

23. Zhu Z, Man X, Xia M, Huang Y, Yuan D, Huang S. Collective effects of SNPs on transgenerational inheritance in Caenorhabditis elegans and budding yeast. *Genomics* 2015; **106**(1)**:** 23-29.

24. Zhu Z, Lu Q, Wang J, Huang S. Collective effects of common SNPs in foraging decisions in Caenorhabditis elegans and an integrative method of identification of candidate genes. *Sci Rep* 2015; **5:** 16904.

25. Zhu Z, Yuan D, Luo D, Lu X, Huang S. Enrichment of Minor Alleles of Common SNPs and Improved Risk Prediction for Parkinson's Disease. *PLoS One* 2015; **10**(7)**:** e0133421.

26. Yuan D, Zhu Z, Tan X, Liang J, Zeng C, Zhang J *et al.* Scoring the collective effects of SNPs: association of minor alleles with complex traits in model organisms. *Sci China Life Sci* 2014; **57**(9)**:** 876-888.

27. He P, Lei X, Yuan D, Zhu Z, Huang S. Accumulation of minor alleles and risk prediction in schizophrenia. *Sci Rep* 2017; **7**(1)**:** 11661.

28. Lei X, Huang S. Enrichment of minor allele of SNPs and genetic prediction of type 2 diabetes risk in British population. *PLoS One* 2017; **12**(11)**:** e0187644.

29. Hu T, Long M, Yuan D, Zhu Z, Huang Y, Huang S. The genetic equidistance result: misreading by the molecular clock and neutral theory and reinterpretation nearly half of a century later. *Sci China Life Sci* 2013; **56**(3)**:** 254-261.

30. Huang S. New thoughts on an old riddle: What determines genetic diversity within and between species? *Genomics* 2016; **108**(1)**:** 3-10.

31. Ponting CP, Hardison RC. What fraction of the human genome is functional? *Genome Res* 2011; **21**(11)**:** 1769-1776.

32. Rudner R, Karkas JD, Chargaff E. Separation of B. subtilis DNA into complementary strands. 3. Direct analysis. *Proc Natl Acad Sci U S A* 1968; **60**(3)**:** 921-922.

33. Li X, Scanlon MJ, Yu J. Evolutionary patterns of DNA base composition and correlation to polymorphisms in DNA repair systems. *Nucleic Acids Res* 2015; **43**(7)**:** 3614-3625.

34. Li J, Cai T, Jiang Y, Chen H, He X, Chen C *et al.* Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database. *Mol Psychiatry* 2016; **21**(2)**:** 290-297.

35. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO *et al.* A global reference for human genetic variation. *Nature* 2015; **526**(7571)**:** 68-74.

36. Kimura M, Crow JF. The Number of Alleles That Can Be Maintained in a Finite Population. *Genetics* 1964; **49:** 725-738.

37. Huang S. *Histone methylation and the initiation of cancer*. CRC Press: New York, 2008.

38. Huang S. Inverse Relationship Between Genetic Diversity and Epigenetic Complexity. Available from Nature Precedings http://dx.doi.org/10.1038/npre.2009.1751.2, 2009.

39. Yuan D, Lei X, Gui Y, Zhu Z, Wang D, Yu J *et al.* Modern human origins: multiregional evolution of autosomes and East Asia origin of Y and mtDNA. *bioRxiv* 2017.

40. Hershberg R, Petrov DA. Evidence that mutation is universally biased towards AT in bacteria. *PLoS Genet* 2010; **6**(9)**:** e1001115.

41. Lynch M. Rate, molecular spectrum, and consequences of human mutation. *Proc Natl Acad Sci U S A* 2010; **107**(3)**:** 961-968.